JPRN-jRCT2031210566CompletedPhase 2
Follow ups of patients in AK1830 Phase II Studies
Kudo Katsuyasu0 sites10 target enrollmentStarted: January 21, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Patients who provided written informed consent to participate in the clinical study and who met all of the following criteria
- •[1] Patients who participated in the AK1830 Phase II Study and were deemed to require follow up.
- •[2] Patients who fully understand the contents of the study and are capable of providing informed consent
Exclusion Criteria
- •Patients who met any of the following criteria are to be excluded.
- •[1] Patients who have received their long-term safety outcomes in the AK1830 Phase II Study
- •[2] Patients deemed by the investigator or sub-investigator to be unsuitable for study participation
Investigators
Similar Trials
Unknown
Phase 2
K012 phase II clinical studyColorectal cancerJPRN-jRCT2080220752ippon Kayaku Co., Ltd.
Completed
Phase 2
Randomized, Double-Blind Study of AK1830 in Patients with Pain due to Osteoarthritis of the knee.JPRN-jRCT2080224985Asahi Kasei Pharma Corporation400
Not yet recruiting
Phase 2
Randomized, Double-Blind Study of AK1830 in Patients with Pain due to Osteoarthritis of the knee.Pain due to osteoarthritisJPRN-jRCT2031230469Kudo Katsuyasu400
Completed
Phase 2
Randomized, Double-Blind Study of AK1830 in Patients with low back paiow back painJPRN-jRCT2080225352Asahi Kasei Pharma Corporation400
Not yet recruiting
Phase 2
STUDY ON AKKARAM(STOMATITIS)WITH EVALUATION OF SIDDHA DRUGAKKARAM ENNAICTRI/2021/01/030644Government siddha medical college